Baseline characteristics
| . | Whole cohort (N = 24), n (%) . |
|---|---|
| Age, y | |
| Median (Min, Max) | 72 (30, 85) |
| ≥60 | 20 (83) |
| Sex | |
| Female | 7 (29) |
| Male | 17 (71) |
| Race | |
| White | 20 (83) |
| Black or African American | 3 (12) |
| Asian | 1 (4) |
| Previous SCT | |
| 2 | 2 (8) |
| 1 | 8 (33) |
| No | 14 (58) |
| Prior venetoclax | 21 (88) |
| No. of AML salvage therapies | |
| Median (Min, Max) | 3 (1, 11) |
| ≥3 | 14 (58) |
| No. of previous lines (including AHN) | |
| Median (Min, Max) | 4 (1, 11) |
| ≥3 | 17 (71) |
| Secondary AML | 14 (58) |
| ELN 2022 risk stratification | |
| Favorable | 0 (0) |
| Intermediate | 0 (0) |
| Adverse | 24 (100) |
| Cytogenetics | |
| Favorable | 0 (0) |
| Diploid | 5 (21) |
| Intermediate nondiploid | 8 (33) |
| Adverse noncomplex | 1 (4) |
| Complex | 8 (33) |
| Insufficient metaphases | 2 (8) |
| Mutations | |
| ASXL1 | 11 (46) |
| BCOR | 3 (12) |
| CBL | 4 (17) |
| DNMT3A | 4 (17) |
| FLT3ITD | 0 (0) |
| NPM1 | 0 (0) |
| NRAS | 4 (17) |
| PTPN11 | 5 (21) |
| RUNX1 | 24 (100) |
| SF3B1 | 2 (8) |
| SRSF2 | 8 (33) |
| TET2 | 8 (33) |
| TP53 | 1 (4) |
| WT1 | 3 (12) |
| ZRSR2 | 1 (4) |
| Splicing | 11 (46) |
| Signaling | 12 (50) |
| Tumor Suppressor | 6 (25) |
| Methylation | 12 (50) |
| Chromatin Modifiers | 12 (50) |
| Cohesin | 2 (8) |
| Median mutation count (Min, Max) | 5 (2, 9) |
| . | Whole cohort (N = 24), n (%) . |
|---|---|
| Age, y | |
| Median (Min, Max) | 72 (30, 85) |
| ≥60 | 20 (83) |
| Sex | |
| Female | 7 (29) |
| Male | 17 (71) |
| Race | |
| White | 20 (83) |
| Black or African American | 3 (12) |
| Asian | 1 (4) |
| Previous SCT | |
| 2 | 2 (8) |
| 1 | 8 (33) |
| No | 14 (58) |
| Prior venetoclax | 21 (88) |
| No. of AML salvage therapies | |
| Median (Min, Max) | 3 (1, 11) |
| ≥3 | 14 (58) |
| No. of previous lines (including AHN) | |
| Median (Min, Max) | 4 (1, 11) |
| ≥3 | 17 (71) |
| Secondary AML | 14 (58) |
| ELN 2022 risk stratification | |
| Favorable | 0 (0) |
| Intermediate | 0 (0) |
| Adverse | 24 (100) |
| Cytogenetics | |
| Favorable | 0 (0) |
| Diploid | 5 (21) |
| Intermediate nondiploid | 8 (33) |
| Adverse noncomplex | 1 (4) |
| Complex | 8 (33) |
| Insufficient metaphases | 2 (8) |
| Mutations | |
| ASXL1 | 11 (46) |
| BCOR | 3 (12) |
| CBL | 4 (17) |
| DNMT3A | 4 (17) |
| FLT3ITD | 0 (0) |
| NPM1 | 0 (0) |
| NRAS | 4 (17) |
| PTPN11 | 5 (21) |
| RUNX1 | 24 (100) |
| SF3B1 | 2 (8) |
| SRSF2 | 8 (33) |
| TET2 | 8 (33) |
| TP53 | 1 (4) |
| WT1 | 3 (12) |
| ZRSR2 | 1 (4) |
| Splicing | 11 (46) |
| Signaling | 12 (50) |
| Tumor Suppressor | 6 (25) |
| Methylation | 12 (50) |
| Chromatin Modifiers | 12 (50) |
| Cohesin | 2 (8) |
| Median mutation count (Min, Max) | 5 (2, 9) |
AHN, antecedent hematologic neoplasm; ELN, European LeukemiaNet; Max, maximum; Min, minimum.